FDA eases restrictions on the glucose-lowering drug rosiglitazone

M Mitka - Jama, 2013 - jamanetwork.com
Dismissing concerns previously raised about increased risk of myocardial infarction and
cardiac death associated with the diabetes drug rosiglitazone (Avandia), the US Food and
Drug Administration (FDA) announced November 25 that it was lifting most restrictions on
prescribing and use of the blood glucose–lowering drug. Rosiglitazone gained FDA
approval in 1999 and quickly became a multibillion blockbuster product for its manufacturer,
GlaxoSmithKline (then SmithKline Beecham). But cardiovascular safety concerns were soon …